Arcus Biosciences, Inc. Increase (Decrease) in Accrued Liabilities
Arcus Biosciences, Inc. (RCUS) reported Increase (Decrease) in Accrued Liabilities of $2.48 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2020-11-05
- Arcus Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2020-09-30 was $1.82M, a 50.12% increase year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2020-06-30 was $13.00K.
- Arcus Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2020-03-31 was $648.00K, a 59.65% decline year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2019-12-31 was $2.85M.
- Arcus Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2019 was $3.50M, a 0.06% increase from fiscal 2018.
- Arcus Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2018 was $3.50M, a 121.05% increase from fiscal 2017.
- Arcus Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2017 was $1.58M, a 95.79% increase from fiscal 2016.
- Arcus Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2016 was $808.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2020-09-30 | $1.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.84M derived: sum of 2 quarters · filed 2020-11-05 | $2.48M 10-Q · filed 2020-11-05 | $5.33M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2020-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $661.00K 10-Q · filed 2020-08-06 | $3.51M derived: sum of 3 quarters · filed 2020-08-06 | $4.72M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2020-03-31 | $648.00K 10-Q · filed 2020-05-05 | $3.50M derived: sum of 2 quarters · filed 2020-05-05 | $4.71M derived: sum of 3 quarters · filed 2020-11-05 | $2.54M derived: sum of 4 quarters · filed 2020-11-05 | ||
| 2019-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $4.06M derived: sum of 2 quarters · filed 2020-11-05 | $1.89M derived: sum of 3 quarters · filed 2020-11-05 | $3.50M 10-K · filed 2020-03-05 | ||
| 2019-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$956.00K derived: sum of 2 quarters · filed 2020-11-05 | $650.00K 10-Q · filed 2020-11-05 | $3.64M 10-Q · filed 2019-11-05 | $6.00K derived: sum of 4 quarters · filed 2020-11-05 | |
| 2019-06-30 | -$2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$565.00K 10-Q · filed 2020-08-06 | $9.53M 10-Q · filed 2019-08-06 | -$1.21M derived: sum of 3 quarters · filed 2020-08-06 | $1.12M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | $1.61M 10-Q · filed 2020-05-05 | $962.00K derived: sum of 2 quarters · filed 2020-05-05 | $3.29M derived: sum of 3 quarters · filed 2020-05-05 | $4.69M derived: sum of 4 quarters · filed 2020-05-05 | ||
| 2018-12-31 | -$644.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $1.69M derived: sum of 2 quarters · filed 2020-03-05 | $3.09M derived: sum of 3 quarters · filed 2020-03-05 | $3.50M 10-K · filed 2020-03-05 | ||
| 2018-09-30 | $2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $3.73M derived: sum of 2 quarters · filed 2019-11-05 | $4.14M 10-Q · filed 2019-11-05 | $5.11M derived: sum of 4 quarters · filed 2019-11-05 | ||
| 2018-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.81M 10-Q · filed 2019-08-06 | $2.78M derived: sum of 3 quarters · filed 2019-08-06 | $2.57M derived: sum of 4 quarters · filed 2019-08-06 | ||
| 2018-03-31 | $410.00K 10-Q · filed 2019-05-02 | $1.38M derived: sum of 2 quarters · filed 2019-05-02 | $1.17M derived: sum of 3 quarters · filed 2019-05-02 | $2.46M derived: sum of 4 quarters · filed 2019-05-02 | ||
| 2017-12-31 | $971.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-05 | $761.00K derived: sum of 2 quarters · filed 2019-03-05 | $2.05M derived: sum of 3 quarters · filed 2019-03-05 | $1.58M 10-K · filed 2019-03-05 | ||
| 2017-09-30 | -$210.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.08M derived: sum of 2 quarters · filed 2018-11-08 | $611.00K 10-Q · filed 2018-11-08 | |||
| 2017-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $821.00K 10-Q · filed 2018-08-06 | ||||
| 2017-03-31 | -$469.00K 10-Q · filed 2018-05-09 | |||||
| 2016-12-31 | $808.00K 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |